Tag Archives: bevacizumab

New Hope for Patients with Advanced Metastatic Colorectal Cancer Patients

Posted on March 11, 2012 by wngai

Colorectal cancer is the fourth most common cancer in men and women with nearly 500,000 deaths due to colorectal cancer every year.  When detected early at localized stage I, the 5-year survival rate can reach 90%. At this stage, surgical … Continue reading →

Posted in Cancer, Colorectal cancer | Tagged , , , , , , , , , , , , , , , , , , | Comments Off on New Hope for Patients with Advanced Metastatic Colorectal Cancer Patients

New Treatment for Colorectal Cancer Patients with Liver Metastases

Posted on April 3, 2011 by wngai

In the past, bevacizumab (Avastin) plus FOLFOX (leucovorin, 5-fluorouracil, and oxaliplatin) is the mainstay treatment for colorectal cancer patients with metastases (Stage IV).  Even though the response rate of this regimen is impressive, less than 10% of Stage IV colorectal cancer … Continue reading →

Posted in Cancer, Colorectal cancer | Tagged , , , , , , , , , , | Comments Off on New Treatment for Colorectal Cancer Patients with Liver Metastases

Bevacizumab Beneficial in Newly Diagnosed Glioblastoma?

Posted on December 22, 2010 by wngai

A large study of patients with newly diagnosed glioblastoma multiforme suggests that the addition of bevacizumab (Avastin) and irinotecan (Camptosar) to standard chemoradiation can extend survival (progression and overall survival) by 6 months.  Bevacizumab (Avastin) is an inhibitor of vascular … Continue reading →

Posted in Cancer, Glioblastma | Tagged , , , , , , , , , | Comments Off on Bevacizumab Beneficial in Newly Diagnosed Glioblastoma?

Efficacy and tolerability of Avastin plus Xeloda as first-line therapy in patients with advanced Liver Cancer

Posted on July 4, 2010 by wngai

Liver cancer is the fifth most common cancer worldwide and the third most common cause of cancer mortality.  More than 80% of cases occur in East Asia and sub-Sharan Africa, and the incidence is increasing in Europe and the US. … Continue reading →

Posted in Cancer, Liver Cancer | Tagged , , , , , , , | Comments Off on Efficacy and tolerability of Avastin plus Xeloda as first-line therapy in patients with advanced Liver Cancer

Avastin Boosts Progression-Free Survival in Ovarian Cancer Patients

Posted on June 26, 2010 by wngai

Adding bevacizumab (Avastin) to chemotherapy, followed by bevacizumab as maintenance therapy, can significantly prolong progression-free survival in women with advanced ovarian cancer.  The study consisted of 1873 women with newly diagnosed stage III (macroscopic residual disease) or stage IV ovarian, primary peritoneal, … Continue reading →

Posted in Cancer, Ovarian Cancer | Tagged , , , , , , | Comments Off on Avastin Boosts Progression-Free Survival in Ovarian Cancer Patients

Pancreatic cancer – Causes, Prevention, Prognosis, Diagnosis and Latest Treatment

Posted on April 17, 2010 by wngai

Prevalence Pancreatic cancer is the fourth most common cause of adult cancer death, accounting for an estimated 42,470 new cases and 35,240 deaths in USA for 2009.  The high mortality rate is due to the high incidence of metastatic disease … Continue reading →

Posted in Pancreatic Cancer | Tagged , , , , , , , , , , , , , , , , | 2 Comments